Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.

MLA

Sun, Xinghuai, et al. “Effectiveness and Safety of Tafluprost in Primary Open-Angle Glaucoma and Ocular Hypertension: A Post-Marketing Phase IV Study in China.” BMC Ophthalmology, vol. 22, no. 1, Aug. 2022, p. 332. EBSCOhost, https://doi.org/10.1186/s12886-022-02553-1.

APA

Sun, X., Liu, Q., Tang, X., Yao, K., Li, Y., Yang, J., Zhang, M., Yuan, H., Zheng, Y., Li, W., & Peng, H. (2022). Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China. BMC Ophthalmology, 22(1), 332. https://doi.org/10.1186/s12886-022-02553-1

Chicago

Sun, Xinghuai, Qinghuai Liu, Xin Tang, Ke Yao, Yan Li, Jin Yang, Mingchang Zhang, et al. 2022. “Effectiveness and Safety of Tafluprost in Primary Open-Angle Glaucoma and Ocular Hypertension: A Post-Marketing Phase IV Study in China.” BMC Ophthalmology 22 (1): 332. doi:10.1186/s12886-022-02553-1.